Vesber

Guangzhou Vesber Biotechnology Co., Ltd. was established on October 30, 2007, located in the Guangdong Medical Valley Industrial Park in Nansha District, Guangzhou. Since its establishment in 2007, the company has successively received funding from a series of government funds, including the National 863 Project, the Twelfth Five-Year Support Plan, the SME Innovation Fund, Guangdong Province's Industry-University-Research Collaboration, and Guangzhou's Science and Technology Plan. It holds 22 patents in the United States, Australia, China, and other countries. Relying on the R&D platform of Zhongshan Ophthalmic Center, the company focuses on the development of innovative ophthalmic products. Its representative product, FCVB, is an internationally pioneering artificial organ designed to save eyeballs, capable of finely simulating the structure and function of the human vitreous body. Since its market launch in 2017, foldable artificial vitreous balloon implant surgeries have been performed in 115 hospitals across 24 provinces in China, with over 100 ophthalmologists serving more than 2,000 patients. Currently, the product has also been used for foldable artificial vitreous balloon implant surgeries in 10 foreign countries, including the United Kingdom, Belgium, Turkey, Greece, Russia, Australia, Pakistan, Latvia, etc., with good clinical outcomes.